The Phase 3 results confirm that Retatrutide at 12mg produces the highest weight loss ever recorded in an obesity medication trial, with nearly 29% average reduction at 68 weeks
Nimitphong, H., Saetung, S., Chanprasertyotin, S., Chailurkit, L
Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutide in the diet-induced obesity mouse model
This blue tint is a visual indicator of the presence of active copper in the formulation
Compounded versions may be more accessible, though they are not identical to the brand-name product and quality can vary between compounding pharmacies
This difference is frequently cited as why rodent findings may not generalize to humans